Sanofi India Board Approves Q3 FY25 Results, Declares Interim Dividend of ₹75 per Share
Sanofi India's board approved Q3 and nine-month FY25 results. Revenue declined, but nine-month profit from continuing operations increased. An interim dividend of ₹75 per share was declared.
The announcement has a high impact as it includes the company's latest quarterly and nine-month financial performance, which are key indicators for investors, and the declaration of a substantial interim dividend, directly affecting shareholder returns.
The sentiment is neutral due to mixed financial results: a decline in revenue and profit for the quarter ended September 30, 2025, from continuing operations compared to the previous year's quarter, but an increase in profit from continuing operations for the nine months ended September 30, 2025. The declaration of a significant interim dividend provides a positive aspect.
Sanofi India Limited's Board of Directors, at its meeting on Wednesday, October 29, 2025, approved the Unaudited Financial Statements for the quarter and nine months ended September 30, 2025. Key financial highlights from continuing operations are: * For the quarter ended September 30, 2025: * Revenue from Operations stood at ₹4,754 crore, compared to ₹5,240 crore for the quarter ended September 30, 2024. * Profit for the period from continuing operations was ₹760 crore, down from ₹822 crore in the corresponding quarter of the previous year. * For the nine months ended September 30, 2025: * Revenue from Operations was ₹14,176 crore, compared to ₹14,983 crore for the nine months ended September 30, 2024. * Profit for the period from continuing operations increased to ₹2,650 crore, from ₹2,224 crore in the same period last year. The Board also declared an Interim Dividend of ₹75 per equity share of face value ₹10 each for the year 2025. The company has fixed Friday, November 7, 2025, as the Record Date for the payment of this Interim Dividend, which will be paid within 30 days from the declaration date.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.